 Tamoxifen
"Tamoxifen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
| Descriptor ID |
D013629
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900
|
| Concept/Terms |
ICI-46474- ICI-46474
- ICI 46474
- ICI46474
- ICI-46,474
- ICI 46,474
- ICI46,474
|
Below are MeSH descriptors whose meaning is more general than "Tamoxifen".
Below are MeSH descriptors whose meaning is more specific than "Tamoxifen".
This graph shows the total number of publications written about "Tamoxifen" by people in this website by year, and whether "Tamoxifen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 1 | 4 | | 1995 | 2 | 0 | 2 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 2 | 2 | 4 | | 2000 | 3 | 1 | 4 | | 2001 | 0 | 1 | 1 | | 2003 | 2 | 1 | 3 | | 2004 | 2 | 2 | 4 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 2 | 3 | 5 | | 2008 | 5 | 1 | 6 | | 2009 | 4 | 2 | 6 | | 2010 | 3 | 4 | 7 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 3 | 4 | | 2013 | 1 | 2 | 3 | | 2014 | 3 | 7 | 10 | | 2015 | 0 | 1 | 1 | | 2016 | 3 | 3 | 6 | | 2017 | 0 | 2 | 2 | | 2018 | 0 | 3 | 3 | | 2019 | 1 | 5 | 6 | | 2020 | 3 | 1 | 4 | | 2021 | 1 | 5 | 6 | | 2022 | 0 | 3 | 3 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tamoxifen" by people in Profiles.
-
Thomas NS, Scalzo RL, Wellberg EA. Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy. Nat Rev Endocrinol. 2024 Jan; 20(1):16-26.
-
Liang J, Ingalla ER, Yao X, Wang BE, Tai L, Giltnane J, Liang Y, Daemen A, Moore HM, Aimi J, Chang CW, Gates MR, Eng-Wong J, Tam L, Bacarro N, Roose-Girma M, Bellet M, Hafner M, Metcalfe C. Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer. Sci Transl Med. 2022 Sep 21; 14(663):eabo5959.
-
Kravets V, Dwulet JM, Schleicher WE, Hodson DJ, Davis AM, Pyle L, Piscopio RA, Sticco-Ivins M, Benninger RKP. Functional architecture of pancreatic islets identifies a population of first responder cells that drive the first-phase calcium response. PLoS Biol. 2022 09; 20(9):e3001761.
-
Lalonde RL, Kemmler CL, Riemslagh FW, Aman AJ, Kresoja-Rakic J, Moran HR, Nieuwenhuize S, Parichy DM, Burger A, Mosimann C. Heterogeneity and genomic loci of ubiquitous transgenic Cre reporter lines in zebrafish. Dev Dyn. 2022 10; 251(10):1754-1773.
-
Friedman JC, Buyers E, Laurin J, Hampanda K, Alaniz VI. Tamoxifen for the Treatment of Etonogestrel Implant-Associated Bleeding in an Adolescent Gynecology Practice. J Pediatr Adolesc Gynecol. 2022 Jun; 35(3):341-345.
-
Scalzo RL, Foright RM, Hull SE, Knaub LA, Johnson-Murguia S, Kinanee F, Kaplan J, Houck JA, Johnson G, Sharp RR, Gillen AE, Jones KL, Zhang AMY, Johnson JD, MacLean PS, Reusch JEB, Wright-Hobart S, Wellberg EA. Breast Cancer Endocrine Therapy Promotes Weight Gain With Distinct Adipose Tissue Effects in Lean and Obese Female Mice. Endocrinology. 2021 11 01; 162(11).
-
Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, Cherian M, Stover DG, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2021 Nov; 190(2):183-188.
-
Stout MB, Scalzo RL, Wellberg EA. Persistent Metabolic Effects of Tamoxifen: Considerations for an Experimental Tool and Clinical Breast Cancer Treatment. Endocrinology. 2021 09 01; 162(9).
-
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, Saura C, Shimizu C, S?tersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HC, Saunders C, Cardoso F, Susnjar S, Bjelic-Radisic V, Smith KL, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O. Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast. 2021 Oct; 59:327-338.
-
Sottnik JL, Bordeaux EK, Mehrotra S, Ferrara SE, Goodspeed AE, Costello JC, Sikora MJ. Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast. Mol Cancer Res. 2021 08; 19(8):1270-1282.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|